6/29/23, 1:41 AM POISE-2 (aspirin) Pathway Feedback Search Clinical Topics Home Studies POISE 2 (aspirin) POISE 2 (aspirin) Disease Perioperative management of an Trial question What is the role of aspirin in patients undergoing noncardiac surgery? Study design Multi-center Double blinded RCT Population Characteristics of study participants 47.0% female N = 10010 53.0% male 10010 patients (4727 female, 5283 male) Inclusion criteria: patients undergoing noncardiac surgery who were at risk for vascular complications Key exclusion criteria: hypersensitivity or known allergy to aspirin, consumption of aspirin within 72 hours prior to surgery, systolic BP < 105 m Hg, active peptic ulcer disease or gastrointestinal bleeding within 6 weeks before surgery, undergoing intracranial surgery, carotid endarterectomy, or retinal surgery Interventions N=4998 aspirin (at a dose of 200 mg before surgery and continued daily at a dose of 100 mg for 30 days in the initiation stratum and for 7 days in the continuation stratum) N=5012 placebo (matching dose) https://web.pathway.md/studies/recr5nHBPuC6cDvAR 1/2 6/29/23, 1:41 AM POISE-2 (aspirin) Pathway Primary outcome Death or nonfatal myocardial infarction at 30 days 7.1 % 7.1 7 5.3 % 3.5 % 1.8 % No significant difference 0.0 % Aspirin Placebo No significant difference in death or nonfatal myocardial infarction at 30 days (7% vs. 7.1%; HR 0.99, 99% CI 0.86 to 1.15) Secondary outcomes No significant difference in myocardial infarction (6.2% vs. 6.3%; HR 0.98, 95% CI 0.84 to 1.15) Safety outcomes Significant differences in major bleeding (4.6% vs. 3.8%, p = 0.04; HR 1.23, 95% CI 1.01 - 1.49). Conclusion In patients undergoing noncardiac surgery who were at risk for vascular complications, aspirin was not superior to placebo with respect to death or nonfatal myocardial infarction at 30 days. Reference Devereaux PJ, Mrkobrada M, Sessler DI et al. Aspirin in patients undergoing noncardiac surgery. N Engl J Med. 2014 Apr 17;370(16):1494-503. Open reference URL https://web.pathway.md/studies/recr5nHBPuC6cDvAR 2/2